November 05, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : ***Intimation of grant of Employee Stock Options under HealthCare Global Enterprises Limited- Employee Stock Option Scheme, 2026***

Stock Code : ***BSE – 539787, NSE – HCG***

Reference : ***Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations"), read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026.***

We would like to inform you that the Nomination and Remuneration Committee of the Board of Directors of the Company, at its meeting held today, i.e., November 05, 2026, has approved grant of Employee Stock Options to the eligible employees of the Company and its subsidiary company(ies) and associate company(ies), in India or outside India, under the HealthCare Global Enterprises Limited-Employee Stock Option Scheme, 2026 (**"HCG ESOS 2026"**).

The Nomination and Remuneration Committee meeting commenced at 11.00 a.m. IST and concluded at 11.15 a.m. IST.

Detailed information in this regard in accordance with Regulation 30 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026, is annexed herewith as **Annexure-A**.

The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/

You are requested to take the information on record.

Thanking You,

For **HealthCare Global Enterprises Limited**

SUNU MANUEL ABEY
Digitally signed by SUNU MANUEL ABEY
Date: 2026.11.05 20:29:25 +05'30'

Sunu Manuel
Company Secretary and Compliance Officer.

ANNEXURE – A

Disclosures under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023, and last updated on January 30, 2026, with respect to grant of Employee Stock Options under HCG ESOS 2026.

Sr. No.	Particulars	Details
1.	Brief details of options granted.	70,000 (Seventy Thousand) options have been granted by the Nomination and Remuneration Committee in terms of the **HCG ESOS 2026.**
2.	Whether the scheme is in terms of SEBI (SBEB) Regulations, 2021 (if applicable).	Yes
3.	Total number of shares covered by these options.	70,000 (Seventy Thousand) shares. On exercise of options, each option would be converted into one equity share of the Company having face value of INR 10/- each fully paid-up.
4.	Pricing Formula.	Exercise Price: INR 495 per share
5.	Options Vested.	Not applicable at this stage. Options granted shall have a vesting period as determined by the Nomination and Remuneration Committee which shall: (i) not be less than 1 (one) year from the grant date and (ii) not exceed 7 (seven) years from the grant date.
6.	Time within which option may be exercised.	The exercise period shall be a maximum period of 10 (ten) years from the grant date, commencing after the expiry of 6 (six) years from the grant date or upon the occurrence of a change in control event, whichever is earlier. In the event a change in control occurs, the grantee shall have a period of 6 (six) months from the date of such change in control event, to exercise the vested options, provided that where the change in control occurs prior to the expiry of 1 (one) year from the grant date, such period shall commence only upon the expiry of 1 (one) year from the grant date.

7.	Options exercised.	Not applicable at this stage.
8.	Money realized by exercise of options.	Not applicable at this stage.
9.	The total number of shares arising as a result of exercise of option.	Not applicable at this stage.
10.	Options Lapsed.	Not applicable at this stage.
11.	Variation of terms of options.	Not applicable at this stage.
12.	Brief details of significant terms.	The significant terms of HCG ESOS 2026 are the same as disclosed under the postal ballot notice.
13.	Subsequent changes or cancellation or exercise of such options.	Not applicable at this stage.
14.	Diluted earnings per share pursuant to issue of equity shares on exercise of options.	Not applicable at this stage.